-+ 0.00%
-+ 0.00%
-+ 0.00%
The Zhitong Finance App learned that an analysis of insurance claim data found that if GLP-1 drugs for weight loss and diabetes were priced below $350 per month, payers — such as employers and plan sponsors — would achieve net savings due to reduced usage of related medical services.
Share
Listen to the news
The Zhitong Finance App learned that an analysis of insurance claim data found that if GLP-1 drugs for weight loss and diabetes were priced below $350 per month, payers — such as employers and plan sponsors — would achieve net savings due to reduced usage of related medical services.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending